ArticlePsychopharmacology2015
A longitudinal study of self-reported psychopathology in early ecstasy and amphetamine users.
Article in Psychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Illicit Drug Use and Associated Problems in the Nightlife Scene: A Potential Setting for Prevention.International journal of environmental research and public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsIt still remains unclear whether psychopathological abnormalities described in human 3,4-methylenedioxymethamphetamine users (MDMA users) and d-amphetamine users (AMPH users) existed before the beginning of regular use or if they develop with ongoing use.
objectivesThe present study was conducted in order to assess this relationship and to overcome previous methodological shortcomings.
methodsA longitudinal cohort study in 96 beginning MDMA and d-amphetamine users between 2006 and 2011 with a follow-up duration of 24 months. In order to explore the impact of MDMA and AMPH use on self-reported psychopathology (measured by the Symptom Checklist-90-Revised), mixed models for repeated measures were fitted. In order to examine the impact of previous psychopathology on subsequent use, partial correlation analyses and linear regression analyses were applied.
resultsOver the course of the 2-year follow-up period, 31 subjects used neither MDMA nor AMPH (non-users); 65 subjects used both MDMA and AMPH: 37 subjects used between 1 and 14 tablets of MDMA and 28 subjects used 15 or more tablets of MDMA. Thirty-three subjects used between 1 and 14 g of AMPH, and 32 subjects used 15 g or more. No associations concerning MDMA/AMPH use and development of self-reported psychopathology were found. However, there was a significant relationship between globally increased self-reported psychopathology-particularly psychoticism-at the beginning of the study and subsequent AMPH use.
conclusionsThe data of the present study suggest that a certain psychopathological profile could form a risk factor for later use of amphetamines.
Indexed as
Identifiers
25155312What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.